| Corcept Therapeutics is a commercial-stage company engaged in the discovery and development of medications that treat severe metabolic, oncologic and psychiatric disorders by modulating the effect of the hormone cortisol. The U.S. Food and Drug Administration has approved Korlym® 300 mg tablets, as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. Co. has discovered and patented four structurally series of selective cortisol modulators, consisting a variety of compounds. We show 43 historical shares outstanding datapoints in our CORT shares outstanding history coverage, used to compute CORT market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CORT market cap history over the course of time is important for investors
interested in comparing CORT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CORT versus a peer is one thing; comparing
CORT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CORT can fluctuate over the course of history.
With this page we aim to empower investors researching CORT by allowing them to research the CORT market cap history.